移植肾单克隆IgG沉积增生性肾小球肾炎早期复发率高
该回顾性研究纳入26例移植肾单克隆免疫球蛋白G沉积增生性肾小球肾炎(PGNMID)患者,其中16例接受早期方案活检。PGNMID在多数(89%)患者中为复发性疾病,诊断活检中位时间为移植后5.5个月,86%在移植后3-4个月内检出。随访期间11/25例移植物丢失,中位移植物生存92个月,独立预测因素为峰值蛋白尿更高和移植至诊断时间更长。
要点
- 移植肾PGNMID多为复发,86%在移植后3-4个月内检出。
- 诊断后近半数患者3年内丢失移植物,中位生存92个月。
- 峰值蛋白尿高和诊断延迟是移植物丢失独立预测因素。
核心结论
- PGNMID在移植肾中复发率高且发生早,方案活检可提高早期检出。
- 移植物预后不佳,近半数患者在诊断后3年内丢失移植物。
研究设计与样本
- 回顾性识别26例移植肾PGNMID患者,其中16例接受早期方案活检随访。
- 从移植植入起平均随访87个月。
主要发现
- 89%患者为复发性PGNMID。
- 诊断活检中位时间为移植后5.5个月,86%在移植后3-4个月内检出。
- 诊断活检最常见模式为系膜增生性肾小球肾炎,89%病例显示IgG3亚型限制。
- 20%患者可检测到血清副蛋白。
- 25例中11例丢失移植物,主要因PGNMID,平均在诊断后36个月内。
关键数值与推荐
- 16例接受免疫抑制治疗,60%患者蛋白尿减少超过50%,13例中9例肾小球病理改善。
- 44%的应答者随后复发。
临床怎么用
- 对移植肾PGNMID应提高警惕,早期方案活检有助于在移植后3-4个月内检出复发。
- 监测峰值蛋白尿和缩短移植至诊断时间可能有助于改善移植物结局。
- 免疫抑制治疗可使部分患者蛋白尿减少和病理改善,但复发率较高。
局限性
- 回顾性研究,样本量较小(26例)。
- 部分患者接受早期方案活检随访,可能存在检测偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The characteristics of allograft proliferative glomerulonephritis with monoclonal immunoglobulin G deposits (PGNMID) are not well defined. To better characterize this disease we retrospectively identified 26 patients with allograft PGNMID, including 16 followed with early protocol biopsies. PGNMID was found to be a recurrent disease in most (89%) patients. A diagnostic biopsy was done for proteinuria and/or increased creatinine in most patients. Median time from transplant to diagnostic biopsy was 5.5 months, with detection within three to four months post-transplant in 86% of patients. Mesangial proliferative glomerulonephritis was the most common pattern on the diagnostic biopsy with 89% of cases showing immunoglobulin G3 subtype restriction. A detectable serum paraprotein was present in 20% of patients. During a mean follow up of 87 months from implantation, 11 of 25 patients lost their allograft largely due to PGNMID within a mean of 36 months from diagnosis. Median graft survival was 92 months. Independent predictors of graft loss were a higher degree of peak proteinuria and longer time from implantation to diagnosis. Sixteen patients were treated with immunosuppressive therapy which resulted in over 50% reduction in proteinuria in 60%, and improvement of glomerular pathology in nine of 13 patients. However, 44% of responders subsequently relapsed. Thus, PGNMID has a high recurrence rate in renal allografts occurring early with detection enhanced by protocol biopsies. Graft outcome is guarded as nearly half of patients lose their graft within three years from diagnosis. Hence, there is a need for better treatment strategies for this disease.
引用
- Said SM, Cosio FG, Valeri AM, et al. Proliferative glomerulonephritis with monoclonal immunoglobulin G deposits is associated with high rate of early recurrence in the allograft. Kidney Int. 2018. PMID: 29716794. doi:10.1016/j.kint.2018.01.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。